Connect with us
Prague Gaming & TECH Summit 2024

Fintech PR

NeoPhore raises an additional £9.6m (USD $12.2m) Series B financing extension to further progress drug discovery pipeline

Published

on

neophore-raises-an-additional-96m-(usd-$12.2m)-series-b-financing-extension-to-further-progress-drug-discovery-pipeline
  • Italian investors, NEVA SGR, LIFTT and Simon Fiduciaria, join the existing syndicate
  • Additional investment brings the total Series B financing to £31.1 million (approx. USD $39.5 million)

LONDON, Feb. 1, 2024 /PRNewswire/ — NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces a further extension of £9.6m (approx. USD $12.2m) to its Series B financing round. With participation from its existing syndicate, CPF managed by Sixth Element Capital, Claris Ventures, Astellas Venture Management, 3B Future Health Fund, 2investAG, and the addition of three new investors – NEVA SGR (the venture capital arm of Intesa Sanpaolo banking group), LIFTT (the venture capital focused on deep-tech chaired by Stefano Buono) and Simon Fiduciaria (the fiduciary company of Ersel Group). This extension brings the total raised in Series B financing to £31.1m (approx. USD $39.5m).

NeoPhore is building a pipeline of small molecule drugs targeting novel proteins across the DNA mismatch repair (‘MMR’) pathway to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients. NeoPhore’s first-in-class MMR inhibitors induce neoantigen expression and increase immunogenicity in solid tumours that become exquisitely sensitive to immunotherapy.

2023 was a great year of progress for NeoPhore. At AACR-NCI-EORTC in Boston in October, the first disclosure of lead compound NP1867 was presented. This demonstrated that NP1867 functionally inhibits MMR in cells and elicits COSMIC mutational signatures consistent with MMR-deficient patient samples.

The additional Series B funding will be used to progress NeoPhore’s lead oral program, through early pre-clinical development.

Dr Matthew Baker, Chief Executive Officer of NeoPhore, said: “NeoPhore has made excellent progress throughout 2023. With the support of our committed and new investors, along with our research collaborations with academic institutions that are in place, we remain on track to deliver a candidate drug for our lead PMS2 program by early 2025.”

Dr Robert James, Chairman of NeoPhore, said: “Over the past years NeoPhore has made tremendous strides in showing that it is possible to target the MMR pathway with small molecule inhibitors.  The recent data the Company has generated and presented at an international conference leads us to believe that NeoPhore’s approach may be profoundly important.  We are pleased to welcome three new Italian-based investors to our syndicate as well as further funding from existing investors. Their commitment reflects the potential value of NeoPhore’s approach that exploits the dynamics of cancer neoantigen evolution, through the discovery and design of effective, well-tolerated medicines that will become a key part of the next-generation of cancer immunotherapies. We are very excited about the next stage in the life of the Company.”

About NeoPhore Ltd

NeoPhore, UK is focused on the discovery and development of novel small molecule therapies to treat cancer through stimulation of the immune system. Generation of cancer neoantigens in tumours can be exploited by the patients’ immune system to overcome natural defence mechanisms in cancer. The Company’s approach targets the DNA mismatch repair (MMR) pathway, which has been proven to promote neoantigen creation and subsequent immunity against numerous cancers. Using these insights, NeoPhore aims to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients. NeoPhore was spun-out of the University of Turin and PhoreMost Ltd by the CRT Pioneer Fund. For more information, please visit www.neophore.com

About NEVA SGR

Neva SGR, venture capital arm of the Intesa Sanpaolo Group and wholly owned by the Intesa Sanpaolo Innovation Center, plans and manages investment funds for professional investors interested in seizing diversification and high-yield opportunities offered by Venture Capital investments. Neva SGR can count on Intesa Sanpaolo Innovation Center’s and Intesa Sanpaolo Group’s strength, financial resources, know-how and network of relationships, a unique source of value on the market. Neva SGR can watch trends and markets from a privileged position and takes action with the strength and the responsibility of Italy’s leading banking group. Intesa Sanpaolo Innovation Center has invested in Neva First, the investment fund designed for excellent, high-tech, high-innovation start-ups, which take advantage of trends with exponential growth potential.

To learn more visit www.nevasgr.com

About LIFTT

Chaired by the scientist and entrepreneur Stefano Buono, LIFTT’s aim is to encourage technology development and transfer from University to Industry, but also to clear the way from a simple business idea to the creation of an innovative product, offering a dynamic and modern vision of venture capital as applied to Technology Transfer. To date, LIFTThas raised EUR 103,5 million and has completed 47 investments, from a pipeline of +3000 companies, operating in all market sectors, with a particular focus on Deep Tech. www.liftt.com Head of Communications & Investor relations: [email protected]

About Simon Fiduciaria

Simon Fiduciaria is the fiduciary and trust company of Ersel Group which since 1936 has been a specialist in wealth management and a unique company in Italy for its absolute independence, professionalism, quality of service, and direct and personal relationship with the client.

Founded in 1986, Simon Fiduciaria stands out for its independence as well as its operational and professional qualities, to fully meet the needs of its customers. As a reference point for the Italian fiduciary market, with over 7 billion administered assets, Simon Fiduciaria has developed, alongside fiduciary and trust heading services, an innovative service dedicated to large private and institutional assets, with independent and analytical monitoring that offers an aggregated view of allocation, performance, and risks, and highlights potential areas for improvement.

About Sixth Element Capital LLP and the CRT Pioneer Fund

Sixth Element Capital LLP (6EC) is a UK based fund manager, which manages the CRT Pioneer Fund. 6EC’s experienced partners focus on creative and collaborative novel financing solutions designed to fund and manage innovative science in order to bring new therapeutic products and technologies to market, creating long term value and benefit to stakeholders. The CRT Pioneer Fund is a specialist oncology investment fund established by 6EC in 2012. The £70 million fund is dedicated to investments in oncology development programmes in Europe. The fund was established to bridge the investment gap between cancer drug discovery and early clinical development.

For more information, please see www.sixthelementcapital.com

About Claris Ventures

Claris Ventures is a biotech-focused venture capital firm based in Turin (Italy). Its first fund under management, Claris Biotech I, was launched in 2020 to finance high potential biopharma companies arisen from the Italian R&D ecosystem – both local and international. We identify and support innovation in the pharmaceutical space, investing in new companies with transformational drugs under development. We aim at the highest impact possible on highly unmet patients’ needs, building value around strong science. Our pursuit for high potential projects involves every research center, clinical structure and company in the Italian life sciences network, whether the founding team is based in Italy or it includes Italian scientists abroad who have strong links with Italy.

http://www.clarisventures.com/

About 3B Future Health Fund II

3B Future Health Fund II S.C.A. SICAV-RAIF is a Luxembourg based investment fund investing in oncology and rare disease therapeutics in Europe and the United States. The firm’s goal is to identify innovative and promising companies that are developing First-in-Class therapeutics for indications with high unmet patient needs and provide them with the financial resources and strategic guidance they need to succeed. The fund targets companies with strong management teams, a solid scientific foundation, and a clear path to regulatory approval and commercialization. We seek to invest in early-stage companies with promising preclinical data. Additionally, the fund’s investment team has extensive experience in the pharma industry, a track record of success in drug development and identifying high-potential investments. 3B is committed to creating value for its investors while also making a positive impact on the lives of patients. For more information please see www.3bfuturehealth.com

About Astellas Venture Management LLC

Astellas Venture Management LLC (AVM) is the corporate venture capital organization dedicated to reinforcing Astellas Pharma Inc. (Astellas) to accomplish the strategic goals. The venture capital activity of AVM is designated since 2005. Astellas, the ultimate parent company of AVM, headquartered in Tokyo is actively engaged in business as an R&D-driven global pharmaceutical company with the business philosophy to “Contribute toward improving the health of people around the world through the provision of innovative and reliable pharmaceutical products”. Through strategic investments in private early-stage companies, the funds aim to mutual-interact with Astellas, leading to partnering/collaboration in the future. AVM will be able to provide portfolio companies with invaluable R&D advice and assistance.

About 2Invest

2Invest AG (2Invest) is an investment company listed on Frankfurt market formed in 2020 from the restructuring of businesses of 4basebio AG.  Our investment objective is primarily but not exclusively to identify and support emerging companies with both strong management teams and ground-breaking technologies in the biotechnology, life sciences and IT sectors. Our ambition is to enable those companies to reach new and meaningful value inflexion points.

View original content:https://www.prnewswire.co.uk/news-releases/neophore-raises-an-additional-9-6m-usd-12-2m-series-b-financing-extension-to-further-progress-drug-discovery-pipeline-302049681.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Fintech PR

Bybit’s P2P Platform Sets New Standards for Crypto/Fiat Swaps and Zero Fees

Published

on

bybit’s-p2p-platform-sets-new-standards-for-crypto/fiat-swaps-and-zero-fees

DUBAI, UAE, Feb. 23, 2024 /PRNewswire/ — Bybit, one the world’s top three crypto exchanges by volume, is proud to announce the introduction of a zero-fee structure for its peer-to-peer (P2P) trading platform, a move set to revolutionize the P2P market.

This innovative policy, applicable to all fiat trading pairs on the platform, is designed to enhance brand visibility in the Malay market and underscores Bybit’s unwavering commitment to safety and customer satisfaction.

At the heart of Bybit’s P2P platform is a robust escrow service, ensuring that the crypto amount in a seller’s ad is securely locked during transactions to protect buyers from potential scams. “Our priority has always been the safety and satisfaction of our users,” said Ben Zhou, co-founder and CEO. “With our zero-fee P2P trading platform we are nurturing a secure ecosystem where our community can trade with peace of mind.”

The platform’s dedication to security is matched by its comprehensive customer support system. Traders are encouraged to report any suspicious activity, with Bybit’s support team standing by to resolve disputes and ensure fair play. This commitment is further bolstered by continuous system enhancements, and stringent risk control measures.

Bybit’s P2P platform offers a user-friendly interface across both mobile and web platforms, making it convenient for users to swap fiat and crypto pairs. With over 570 payment methods and support for more than 60 local currencies, coupled with a simple three-step trading process, Bybit is setting a new standard for efficiency and accessibility in the cryptocurrency trading space.

“By introducing a zero-fee structure and reinforcing our platform with top-notch safety features, we aim to empower traders and promote a culture of transparency and collective trust within our vibrant community,” Zhou added.

#Bybit / #TheCryptoArk

About Bybit

Bybit is one of the world’s  top three crypto exchanges by volume with 20 million users. Established in  2018, it offers a professional platform where crypto investors and traders can find an ultra-fast matching engine, 24/7 customer service, and multilingual community support. Bybit is a proud partner of Formula One’s reigning Constructors’ and Drivers’ champions: the Oracle Red Bull Racing team.

For more details about Bybit, please visit Bybit Press.
For media inquiries, please contact: [email protected].
For more information, please visit: https://www.bybit.com 
For updates, please follow: Bybit’s Communities and Social Media

Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube

Bybit Logo

Photo – https://mma.prnewswire.com/media/2345306/Image.jpg 
Logo – https://mma.prnewswire.com/media/2267288/Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/bybits-p2p-platform-sets-new-standards-for-cryptofiat-swaps-and-zero-fees-302068690.html

Continue Reading

Fintech PR

J&T Express Sees Strong Growth in Lunar New Year, Showcasing Advantageous Southeast Asia Logistics Network

Published

on

j&t-express-sees-strong-growth-in-lunar-new-year,-showcasing-advantageous-southeast-asia-logistics-network

HONG KONG, Feb. 23, 2024 /PRNewswire/ — J&T Express, a global logistics service operator, announced the company has achieved significant enhancements in parcel volume and delivery efficiency across several key markets in China and Southeast Asia during the recent Lunar New Year, attributing to the company’s continuous operational capacity improvements and early preparations for the holiday season.

Data of J&T Express reveals that over the Lunar New Year period, its average daily parcel delivery time in China improved by approximately 5% compared to the previous year, while the average daily delivery rate increased by approximately 17% year-on-year. In Singapore, there has been an 81% year-on-year increase in its parcel volume, alongside a 9% improvement in average delivery time efficiency. Similarly, in Malaysia, its parcel volume surged by approximately 54% year-on-year.

In addition to China, the Lunar New Year is celebrated as a public holiday in numerous Southeast Asian countries. With the global popularity of e-commerce, ensuring reliable logistics services during the holiday season has become increasingly critical for businesses and consumers alike. As the largest courier service provider in Southeast Asia, J&T Express plays a vital role in meeting this demand.

With the company’s extensive and comprehensive logistics network across multiple countries, coupled with its year-round collaboration with e-commerce platforms and expertise in operating during the Lunar New Year in the Chinese market, J&T Express has significantly bolstered its hardware and personnel and updated the delivery fleet in key markets to meet the challenges of delivering shipments during the holiday season.

For instance, J&T Express Vietnam added over 3,000 delivery personnel before the Lunar New Year, and upgraded more than 100 service points, expanding the operational area by over 7,000 square meters. Additionally, at the end of December 2023, J&T Express Vietnam officially received 140 new trucks from THACO AUTO.

According to a forecast by the Ho Chi Minh City’s Department of Industry and Trade, seasonal purchases are expected to grow by more than 11% in 2024, and the growth trend of social commerce will continue as well. Against the backdrop of a thriving online shopping landscape, the demand for delivery services presents both opportunities and challenges. Recognizing the potential, J&T Express Vietnam has strategically improved and enhanced its service quality to meet the evolving demands. The recent upgrade of the company’s truck fleet not only reflects the company’s clear goal of improving the quality of its transportation services but also helps the company meet the growing demand for deliveries during the holiday season, creating significant benefits for its customers with guaranteed service quality and capacity. With unwavering confidence in the market’s prosperity and a customer-centric approach, J&T Express is poised to seize growth opportunities in Vietnam and is actively accelerating its market capture. It will continue to expand its logistics network and transit centers to ensure optimal operational processes and improve user experience and service quality.

J&T Express is a global logistics service provider. According to Frost & Sullivan, J&T Express was the No. 1 express delivery operator in Southeast Asia by parcel volume in 2022 and had the highest market share in China. The company adopts an innovative business model that combines unified standards with a high degree of regional autonomy. This model balances service quality and flexible decision-making, reduces costs, and enables localized and efficient development in each market. With its self-developed JMS system, J&T Express is able to integrate and manage the full lifecycle of shipments, from order placement and collection to settlement, ensuring efficient operations in each market.

J&T Express has further expanded its express delivery business to five countries in Latin America, the Middle East, and North Africa, building upon its successful operations in China and Southeast Asia. Currently, the company provides express delivery services in 13 countries worldwide.

Looking ahead, J&T Express is committed to enhancing its global logistics network while continuously improving service quality and operational efficiency. The company is eager to establish collaborative partnerships with new industry leaders to deliver high-quality logistics solutions for customers worldwide.

About J&T Express

J&T Express is a global logistics service provider with leading express delivery businesses in Southeast Asia and China, the largest and fastest-growing market in the world. Founded in 2015, J&T Express’ network spans thirteen countries, including Indonesia, Vietnam, Malaysia, the Philippines, Thailand, Cambodia, Singapore, China, Saudi Arabia, the UAE, Mexico, Brazil and Egypt. Adhering to its “customer-oriented and efficiency-based” mission, J&T Express is committed to providing customers with integrated logistics solutions through intelligent infrastructure and digital logistics network, as part of its global strategy to connect the world with greater efficiency and bring logistical benefits to all.

Logo – https://mma.prnewswire.com/media/1721319/JT_Express_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/jt-express-sees-strong-growth-in-lunar-new-year-showcasing-advantageous-southeast-asia-logistics-network-302069773.html

Continue Reading

Fintech PR

United Imaging Showcases AI-Driven Innovations and Expands European Presence at ECR 2024

Published

on

united-imaging-showcases-ai-driven-innovations-and-expands-european-presence-at-ecr-2024

VIENNA, Feb. 23, 2024 /PRNewswire/ — United Imaging, a global leader in medical technology, is showcasing its full portfolio of AI-empowered innovations at the European Society of Radiology (ECR) 2024 in Vienna, Austria.  The company highlights its significant EU growth since establishing its regional headquarters in Poland in 2019.

Dr. Al Zhang, Ph.D, Chairman & Co-CEO of United Imaging, stated, “The theme of this year’s ECR, ‘next-generation radiology,’ aligns seamlessly with our innovation philosophy. We’re not just thinking about today; we’re actively shaping the future. At United Imaging, all our innovations are AI-driven, enhancing clinical workflows and supporting diverse scenarios, solidifying our commitment to delivering value to the global medical community. Our future-ready innovation strategy has propelled us to significant global growth.”

Lukasz MIZERKA, vice president of United Imaging international business and general manager for Europe, added, “Last March, we held our first brand launch at ECR, officially introducing our passion for change to the European market. During the year, we achieved swift progress, extending our footprint to numerous European countries with our high-end equipment, serving as testament to the resonance of our mission of bringing ‘equal healthcare for all’. This year marks both our second ECR and fifth year in Europe, and we’re going to present our full portfolio of groundbreaking products and numerous world-first innovations to showcase our confidence and persistence in Europe. We eagerly await everyone to witness our changes and embrace the bright future ahead.”

In five years, United Imaging has introduced hundreds of systems and reached 16 European countries, offering efficient and professional service. Globally, United Imaging’s products have reached more than 12,000 institutions in over 60 countries, including the U.S., France, Italy, Japan, Korea, and the UAE. Also, the company’s top-tier technologies have led to collaborations with prestigious institutions such as Yale University, UC Davis, Washington University in St. Louis, and University of Texas.

Highlighting the growth at ECR 2024, United Imaging will feature the uMR Jupiter 5T (not CE marked in EU) at ECR 2024, a revolutionary whole-body 5T MRI system. The world’s first whole-body ultra-high field 5T MR, the uMR Jupiter 5T, is a revolutionary whole-body 5T MRI system. It transcends the traditional constraints of ultra-high-field MRI, previously confined to imaging of the brain and selected MSK joints. The potential applications of the uMR Jupiter 5T extend to encompass not only the brain and MSK, but also the abdomen, cardiac, pelvis and other additional anatomical regions. The uMR Jupiter 5T has the potential to eclipse the capabilities of standard 3T MRI machines in resolution and signal-to-noise ratio, delivering clarity that empowers radiologists to ‘see the unseen.’ The uMR Jupiter 5T is also designed to overcome the key hurdles of ultra-high field MRI: image uniformity and radio frequency safety. It fits into existing 3T MRI spaces, signaling a significant advancement in the industry.

Pioneering the digital transformation of medical imaging, the booth will also feature AI platforms for the full portfolio of innovations. The uAIFI is an end-to-end technology platform that revolutionarily enhances MRI with AI-integrated hardware and software, significantly improving image quality and expediting diagnostic processes while enhancing user-friendliness. Pioneering with care, the uAIFI offers a holistic approach across the care continuum. Standout features include ACS, the AI-assisted MR acceleration technology designed to enhance both 2D and 3D imaging, and EasySense respiratory gating and monitoring, offering a unique, belt-free experience for patients while simultaneously streamlining the workflow for healthcare professionals, redefining the image quality standard. Evolving intelligently, this future-oriented, human-centered platform undoubtedly brings a new level of AI integration to uMR systems. In tandem with uMI scanners, uExcel is a multi-dimensional molecular imaging technology platform. It aims to meet the advanced demands for functionality, usability, safety, stability, and scientific research. Combined with uExcel UDP, the ultra-digital-platform detector, uExcel SCAN, the smart scanning toolset, uExcel CARE, the AI reconstruction engine, uExcel QA, the efficient quality control system and uExcel EXPLORE, the suite for scientific research, this platform empowers the exploration with ease and innovation both today and tomorrow, promising a more comfortable experience for patients, and a more effective workflow for doctors. Furthermore, the uVera Technology empowers the DSA system with intuitively bionic ability by intelligence-driven robotics, perception, and imaging. And the All-In-One Solution redefines radiotherapy workflow efficiency from CT simulation to treatment delivery.

Adhering to the “Born with AI” philosophy and aligning with the theme of this year’s ECR, “Next Generation Radiology,” United Imaging Intelligence (UII), an AI company within the United Imaging Group’s portfolio, will demonstrate how the fusion of AI is revolutionizing healthcare, highlighting the company’s comprehensive approach to innovation. At the company’s booth this year, UII is poised to showcase its latest medical AI technological breakthroughs, including groundbreaking AI applications of large medical image models and surgical planning, as well as a full spectrum of medical AI solutions across neurology, cardiology, thoracic care, and oncology.

In terms of novel AI applications, UII will unveil the uAI SAT, a smart annotation tool powered by the large medical image model, as well as the next generation of uAI Pioneer Portal, which is equipped with a goggle-less 3D monitor controlled by hand gestures. The audience will experience advancements in 3D surgical planning for thoracic, hepatobiliary, and urological surgeries. Additionally, with a wide array of clinical solutions, UII will also present its support throughout the entire clinical workflow from imaging and prevention to diagnosis, treatment, follow-up assessment, and research.

Aiming at propelling radiology into a new era of transformation, UII has deployed its innovative products in over 3,000 medical institutions worldwide and formed research and product collaborations in Europe, remaining steadfast in further expanding development and partnerships across the globe, thus universally enhancing medical AI accessibility.

(Notes: Products and features mentioned herein may not be commercially available in all countries. Their future availability cannot be guaranteed.)

Attendees of the ECR are welcome to explore the forefront of radiology at booth 401 – Expo X4, where United Imaging persists in connecting innovation with patient well-being through cutting-edge technologies.

View original content:https://www.prnewswire.co.uk/news-releases/united-imaging-showcases-ai-driven-innovations-and-expands-european-presence-at-ecr-2024-302068566.html

Continue Reading

Trending